127 related articles for article (PubMed ID: 6384162)
41. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
42. Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer.
Abratt RP; Sealy R; Tucker RD; Williams MA; Barnes DR; Johnson MB; Green JA; Cridland JS
Int J Radiat Oncol Biol Phys; 1983 May; 9(5):629-32. PubMed ID: 6853264
[TBL] [Abstract][Full Text] [Related]
43. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
Jones DH; Bleehen NM; Workman P; Walton MI
Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
[TBL] [Abstract][Full Text] [Related]
44. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.
Bleehen NM; Wiltshire CR; Plowman PN; Watson JV; Gleave JR; Holmes AE; Lewin WS; Treip CS; Hawkins TD
Br J Cancer; 1981 Apr; 43(4):436-42. PubMed ID: 7016157
[TBL] [Abstract][Full Text] [Related]
45. The neurotoxicity of radiosensitizing drugs: a biochemical assessment of desmethylmisonidazole (DMM) in the rat.
Rose GP; Taylor JM
Toxicology; 1985 Jan; 34(1):43-56. PubMed ID: 3918357
[TBL] [Abstract][Full Text] [Related]
46. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
47. Fatal misonidazole-induced encephalopathy: an RTOG case report.
Kun LE; Ho KC; Moulder JE
Cancer; 1982 Feb; 49(3):423-6. PubMed ID: 7059905
[TBL] [Abstract][Full Text] [Related]
48. Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study.
Meoz RT; Spanos WJ; Doss L; Johnson R; Wasserman TH
Am J Clin Oncol; 1983 Aug; 6(4):417-22. PubMed ID: 6191560
[TBL] [Abstract][Full Text] [Related]
49. Behavioural and ultrastructural studies of desmethylmisonidazole-induced neurotoxicity in mice.
Chao CF; Subjeck JR; Johnson RJ
Br J Radiol; 1983 Jan; 56(661):27-31. PubMed ID: 6821740
[TBL] [Abstract][Full Text] [Related]
50. Treatment of bladder carcinoma with irradiation combined with misonidazole.
Papavasiliou C; Yiogarakis D; Davillas N; Seretakis L; Pappas J; Licourinas M; Theodorou C; Stathopoulos P; Katsoyianni C; Thanos A
Int J Radiat Oncol Biol Phys; 1983 Nov; 9(11):1631-3. PubMed ID: 6358156
[TBL] [Abstract][Full Text] [Related]
51. Effects of nitroimidazoles on neuronal cells in vitro.
Stevenson MA; Calderwood SK; Coleman CN
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1225-30. PubMed ID: 2523881
[TBL] [Abstract][Full Text] [Related]
52. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group.
Grigsby PW; Winter K; Wasserman TH; Marcial V; Rotman M; Cooper J; Keys H; Asbell SO; Phillips TL
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):513-7. PubMed ID: 10348279
[TBL] [Abstract][Full Text] [Related]
53. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
54. Retreatment of pediatric brain tumors with radiation and misonidazole. Results of a CCSG/RTOG phase I/II study.
Wara WM; Wallner KE; Levin VA; Liu HC; Edwards MS
Cancer; 1986 Oct; 58(8):1636-40. PubMed ID: 3756787
[TBL] [Abstract][Full Text] [Related]
55. Radiation therapy of rat brain tumor using misonidazole as hypoxic cell sensitizer.
Tamura M; Inoue H; Murata M; Koizumi H; Nakamura M; Yonome I; Niibe H
J Cancer Res Clin Oncol; 1985; 109(3):188-92. PubMed ID: 4008513
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of desmethylmisonidazole-induced neurotoxicity in the rat using brainstem auditory evoked potentials.
Edwards MS; Gordon DG; Levin VA
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1377-9. PubMed ID: 6469760
[TBL] [Abstract][Full Text] [Related]
57. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
Panis X; Nguyen TD; Froissart D; Demange L
Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
[TBL] [Abstract][Full Text] [Related]
58. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo.
Overgaard J; Overgaard M; Nielsen OS; Pedersen AK; Timothy AR
Br J Cancer; 1982 Dec; 46(6):904-11. PubMed ID: 7150484
[TBL] [Abstract][Full Text] [Related]
59. Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas. A pilot feasibility study of the Radiotherapy Group of the EORTC.
Ang KK; van der Schueren E; Notter G; Horiot JC; Chenal C; Fauchon F; Raps J; van Peperzeel H; Goffin JC; Vessière M; van Glabbeke M
Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1657-64. PubMed ID: 6818185
[No Abstract] [Full Text] [Related]
60. Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination.
Williams K; Begg E; Wade D; O'Shea K
Clin Pharmacol Ther; 1983 Mar; 33(3):314-21. PubMed ID: 6825387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
